Use of Ceramide C16:0 and Ceramide Synthase 6 in the Treatment and Diagnosis of Multiple Sclerosis

The C16:0-ceramide biomarkers described here, allow both the diagnosis and monitoring of autoimmune disease multiple sclerosis. Moreover the ceramide synthase 6 (CerS6) outlined in this invention serves as target for the treatment of MS.

Further Information: PDF

INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0

Contact
Dr. Otmar Schöller

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

NASA: Mystery of life’s handedness deepens

The mystery of why life uses molecules with specific orientations has deepened with a NASA-funded discovery that RNA — a key molecule thought to have potentially held the instructions for…

What are the effects of historic lithium mining on water quality?

Study reveals low levels of common contaminants but high levels of other elements in waters associated with an abandoned lithium mine. Lithium ore and mining waste from a historic lithium…

Quantum-inspired design boosts efficiency of heat-to-electricity conversion

Rice engineers take unconventional route to improving thermophotovoltaic systems. Researchers at Rice University have found a new way to improve a key element of thermophotovoltaic (TPV) systems, which convert heat…